1
EXHIBIT 10.32
================================================================================
FORMATION AGREEMENT
By and Between
NOVARTIS PHARMACEUTICALS CORPORATION
AND
NOVEN PHARMACEUTICALS, INC.
Dated as of May 1, 1998
================================================================================
2
TABLE OF CONTENTS
Page
----
ARTICLE I
DEFINITIONS AND PRINCIPLES OF CONSTRUCTION...................................2
Section 1.1 Definitions................................................2
Section 1.2 Monetary Terms.............................................3
Section 1.3 Hereof.....................................................3
Section 1.4 Plural and Singular........................................3
Section 1.5 Including..................................................3
ARTICLE II
FORMATION OF THE JOINT VENTURE...............................................3
Section 2.1 Formation..................................................3
Section 2.2 Ownership..................................................3
Section 2.3 Governance of the Company..................................3
ARTICLE III
CONTRIBUTIONS TO THE COMPANY.................................................3
Section 3.1 Novartis Contribution......................................3
Section 3.2 Novens Contribution........................................4
Section 3.3 Closing....................................................4
Section 3.4 Actions at the Closing.....................................4
Section 3.5 Additional Deliveries......................................4
Section 3.6 Simultaneous Transactions..................................5
Section 3.7 Public Announcements.......................................5
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF NOVARTIS...................................6
Section 4.1 Organization and Standing..................................6
Section 4.2 Authority..................................................6
Section 4.3 Consents and Approvals; No Violation.......................6
Section 4.4 No Brokers or Finders......................................6
3
Page
----
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF NOVEN......................................7
Section 5.1 Organization and Standing..................................7
Section 5.2 Authority..................................................7
Section 5.3 Consents and Approvals; No Violation.......................7
Section 5.4 No Brokers or Finders......................................8
ARTICLE V
MISCELLANEOUS................................................................8
Section 6.1 Notices....................................................8
Section 6.2 Entire Agreement; Assignment...............................9
Section 6.3 Parties in Interest........................................9
Section 6.4 Law Governing Agreement...................................10
Section 6.5 Expenses..................................................10
Section 6.6 Headings..................................................10
Section 6.7 Counterparts..............................................10
Section 6.8 Mutual Drafting Acknowledgment............................10
Section 6.9 Amendment and Modification................................10
(ii)
4
FORMATION AGREEMENT (this "Agreement"), dated as of May 1,
1998, by and between Novartis Pharmaceuticals Corporation, a Delaware
corporation ("Novartis"), as the successor-in-interest to the Pharmaceuticals
Division of Ciba-Geigy Corporation, a New York corporation ("Ciba") and Noven
Pharmaceuticals, Inc., a Delaware corporation ("Noven"). Novartis and Noven are
each sometimes referred to individually as a "Party" and collectively as the
"Parties."
WITNESSETH:
WHEREAS, Novartis, as the licensee successor-in-interest to
Ciba, and Noven as the licensor are each parties to a License and Supply
Agreement (which agreements are more particularly described below);
WHEREAS, the Parties desire to form a joint venture (the
"Joint Venture") for the purpose of creating a platform to maintain and grow a
franchise in women's health, focusing initially on the manufacture, marketing
and sale of the 17(beta)-estradiol single active ingredient product in a matrix
currently being marketed by Novartis under the trademark "Vivelle" pursuant to
the License Agreement;
WHEREAS, in connection with the formation of the Joint Venture
and upon the terms of this Agreement, Novartis shall, as its contribution to the
Joint Venture, (i) grant an exclusive sublicense to the Joint Venture of the
License Agreement for a term coextensive with the term of the Joint Venture
(such agreement granting the sublicense in the form of Exhibit A hereto, the
"Sublicense Agreement"), (ii) assign to the Joint Venture certain of its rights
and obligations under the Supply Agreement for a term coextensive with the term
of the Joint Venture (such agreement assigning certain of its rights and
obligations in the form of Exhibit B hereto, the "Limited Assignment
Agreement"), and (iii) grant an exclusive royalty free license to the Joint
Venture of the Vivelle trademark, permitting use of the trademark in connection
with the manufacture, marketing and sale of the Joint Venture's products for a
term coextensive with the term of the Joint Venture (such license in the form of
Exhibit C hereto, the "Trademark License");
WHEREAS, in connection with the formation of the Joint Venture
and upon the terms of this Agreement, Noven shall, as its contribution to the
Joint Venture, pay by wire transfer to the account of the Joint Venture in
immediately available funds cash in the amount of $7,500,000;
WHEREAS, the Parties have agreed that to support the business
and operations of the Joint Venture (i) Novartis shall enter into an agreement
with the Joint Venture to provide distribution, administrative and marketing
services to the Joint Venture (such agreement in the form of Exhibit D hereto,
the "Distribution and Services Agreement") and (ii) Noven shall enter into an
agreement with the Joint Venture to provide marketing and promotional services
to the
5
Joint Venture (such agreement in the form of Exhibit E hereto, the "Marketing
and Promotional Services Agreement").
NOW, THEREFORE, in consideration of the foregoing and the
respective representations, warranties, covenants and agreements contained
herein, and intending to be legally bound hereby, the parties agree as follows:
ARTICLE I
DEFINITIONS AND PRINCIPLES OF CONSTRUCTION
Section 1.1 Definitions. For purposes of this Agreement, the
following terms shall be defined as follows:
"Affiliate" shall mean as to any Person any other Person that
directly or indirectly controls, is controlled by, or is under common control
with such first Person. A Person shall be deemed to control another Person if
such Person possesses, directly or indirectly, the power to direct or cause the
direction of the management, policies and/or decision making of such other
Person, whether through the ownership of voting securities, by contract or
otherwise.
"Consent" shall mean any approval, waiver or authorization of,
or filing or registration with, or notification to, any Person.
"Governmental Authority" shall mean any court, agency or
commission or other governmental authority or instrumentality, whether domestic
or foreign.
"License Agreement" shall mean that certain Restated License
Agreement dated as of November 15, 1991, by and between Noven, as licensor, and
Ciba, as licensee, the rights and obligations of Ciba pursuant to which Novartis
has assumed as the successor-in-interest to Ciba.
"Mutual Release" shall mean the Mutual Release to be executed
by the Parties hereto at Closing, which shall be in substantially the form
attached hereto as Exhibit I.
"Person" shall mean any individual, firm, corporation,
partnership or other entity.
"Supply Agreement" shall mean that certain Supply Agreement by
and between Noven and Ciba dated as of August 31, 1995, the rights and
obligations of Ciba pursuant to which Novartis has assumed as the
successor-in-interest to Ciba.
"Vivelle" shall mean the 17(beta)-estradiol single active
ingredient product in a matrix which Novartis has been marketing and will
continue to market up through the Closing Date under the trademark Vivelle
pursuant to the License Agreement.
"Vivelle II" shall mean the second generation product of
Vivelle which has been designated by Noven as G2E2.
2
6
Section 1.2 Monetary Terms. All monetary terms set forth
herein are expressed in U.S. dollars.
Section 1.3 Hereof. The words "hereof," "herein," "hereto,"
"hereunder" and "hereinafter" and words of similar import, when used in this
Agreement, shall refer to this Agreement as a whole and not to any particular
provision of this Agreement.
Section 1.4 Plural and Singular. The terms defined in the
singular shall have a comparable meaning when used in the plural, and vice
versa.
Section 1.5 Including. The word "including" shall mean
including, without limitation, and the words include and "includes" shall have
corresponding meanings.
ARTICLE III
FORMATION OF THE JOINT VENTURE
Section 2.1 Formation. On the Closing Date (as hereinafter
defined), the Parties shall effect the formation of the Joint Venture through
the formation of a company (the "Company") which shall be organized as a limited
liability company under the laws of the State of Delaware. Prior to the Closing
Date, the Parties shall have taken all actions necessary to cause the
Certificate of Formation of the Company, in the form of Exhibit F hereto (the
"Certificate of Formation"), to be filed with the Secretary of State of the
State of Delaware in compliance with the Delaware Limited Liability Company Act,
as amended.
Section 2.2 Ownership. The capital interests of the Company
shall be owned initially 51% by Novartis and 49% by Noven. Except as may
otherwise be agreed by the Parties, the Company shall have no authorized equity
securities other than the interests to be owned by Novartis and Noven.
Section 2.3 Governance of the Company. The organization,
governance and affairs of the Company, including the rights, duties and
obligations of the Parties as members of the Company, shall be governed by the
terms of the Operating Agreement between the Parties, dated the Closing Date, in
the form of Exhibit G hereto (the "Operating Agreement"). The initial sales and
marketing plan of the Company, as agreed by the Parties, is attached hereto as
Exhibit H.
ARTICLE III
CONTRIBUTIONS TO THE COMPANY
Section 3.1 Novartis' Contribution. Upon the terms of this
Agreement, as of the Closing Date, Novartis, as a contribution to capital of the
Company, (i) executes and delivers the
3
7
Sublicense Agreement, (ii) executes and delivers the Assignment Agreement, and
(iii) executes and delivers the Trademark License (collectively, the "Novartis
Contributed Assets").
Section 3.2 Noven's Contribution. Upon the terms of this
Agreement, as of the Closing Date, Noven, as an initial contribution to capital
of the Company, pays by wire transfer to the account of the Company in
immediately available funds the sum of $7,500,000 (the "Noven Contributed
Assets").
Section 3.3 Closing. The consummation of the transactions
contemplated by this Agreement and the Operating Agreement as set forth in
Sections 3.4, 3.5, 3.6 and 3.7 (the "Closing") shall take place on the date
hereof (the "Closing Date") at the offices of White & Case LLP, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇
▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇▇▇. The transactions contemplated by this
Agreement and the Operating Agreement shall be deemed for all purposes to become
effective as of the Closing Date.
Section 3.4 Actions at the Closing. The following actions
shall be taken at the Closing:
(a) Execution of this Agreement and the Operating Agreement.
Novartis and Noven shall execute and deliver an original counterpart of this
Agreement and the Operating Agreement.
(b) Execution of the Sublicense Agreement, Limited Assignment
Agreement, Trademark License and Distribution and Services Agreement. Novartis
shall execute and deliver and each of Novartis and Noven shall cause the Company
to execute and deliver an original counterpart of the Sublicense Agreement,
Limited Assignment Agreement, Trademark License and Distribution and Services
Agreement.
(c) Execution of the Marketing and Promotional Services
Agreement. Noven shall execute and deliver and each of Novartis and Noven shall
cause the Company to execute and deliver an original counterpart of the
Marketing and Promotional Services Agreement.
(d) Payment of Cash Contribution. Noven shall instruct its
bank to wire from its account to the account of the Company the sum of
$7,500,000.
Section 3.5 Additional Deliveries.
(a) Additional Deliveries by Both Parties.
At the Closing, each of the Parties shall execute and deliver the Mutual Release
in the form attached hereto as Exhibit I.
(b) Additional Deliveries by Novartis. At the Closing Novartis
shall deliver to Noven the following, in each case of a document, then duly
executed or otherwise in proper form:
(i) Secretary's Certificate. A certificate of the
Secretary of Novartis (A) certifying that Novartis is authorized to enter into
this agreement and consummate the transactions contemplated by this Agreement;
and (B) certifying the incumbency of the officers of Novartis duly authorized to
execute and deliver any and all documents to be executed and
4
8
delivered by Novartis pursuant to the terms hereof, the signatures of which
officers shall appear on the face of such certificate and be so certified by
such Secretary.
(ii) Other Documents. Such other documents and
certificates as may be required to be delivered by Novartis at or prior to the
Closing pursuant to the terms of this Agreement or otherwise reasonably required
in connection herewith.
(c) Additional Deliveries by Noven. At the Closing Noven shall
deliver to Novartis the following, in each case of a document, then duly
executed or otherwise in proper form:
(i) Secretary's Certificate. A certificate of the
Secretary of Noven (A) certifying and attaching true and correct copies of the
resolutions, in full force and effect as of the Closing Date, of the Board of
Directors of Noven authorizing and approving this Agreement and the consummation
of the transactions contemplated by this Agreement; and (B) certifying the
incumbency of the officers of Noven duly authorized to execute and deliver any
and all documents to be executed and delivered by Noven pursuant to the terms
hereof, the signatures of which officers shall appear on the face of such
certificate and be so certified by such Secretary.
(ii) Other Documents. Such other documents and
certificates as may be required to be delivered by Noven at or prior to the
Closing pursuant to the terms of this Agreement or otherwise reasonably required
in connection herewith.
Section 3.6 Simultaneous Transactions. All of the deliveries
contemplated by this Agreement to be made at the Closing shall be deemed to be
made simultaneously, and no such transaction shall be deemed to have been
consummated until all such transactions have been consummated.
Section 3.7 Public Announcements. Neither Novartis nor Noven
nor any of their Affiliates shall issue any public report, statement or press
release or otherwise make any public statement with respect to this Agreement
and the Operating Agreement and the transactions contemplated hereby and thereby
prior to the Closing Date without prior consultation with and approval of the
other Party (which approval shall not be unreasonably withheld or delayed),
except as may be required by law or securities exchange regulations applicable
to any such Party, in which case such Party shall advise the other Party and
discuss the contents of the disclosure before issuing any such report, statement
or press release. In addition, neither Novartis nor Noven nor any of their
Affiliates shall make any general communication to suppliers, lenders,
creditors, distributors, employees, customers or others having business or
financial relationships with Novartis, Noven or any of their Affiliates
pertaining to this Agreement and the Operating Agreement and the transactions
contemplated hereby and thereby, without the prior written approval of the other
Party (which approval will not be unreasonably withheld or delayed). Prior to
the Closing Date, each Party shall prepare a press release concerning the
execution of this Agreement and the Operating Agreement and the transactions
contemplated hereby and thereby; and shall submit such press release to the
other Party for its review and consent.
5
9
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF NOVARTIS
Novartis makes the following representations and warranties to
Noven, each of which is true and correct on the date hereof:
Section 4.1 Organization and Standing. Novartis is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware
Section 4.2 Authority. Novartis has all requisite corporate
power and authority to execute, deliver and perform its obligations under this
Agreement and the other documents and instruments to be executed and delivered
by Novartis pursuant hereto and to consummate the transactions contemplated
hereby and thereby. The execution and delivery of this Agreement and the other
documents and instruments to be executed and delivered by Novartis pursuant
hereto and the consummation of the transactions contemplated hereby and thereby
have been duly authorized by the Board of Directors of Novartis. No other or
further corporate act or proceeding on the part of Novartis or its shareholders
is necessary to authorize this Agreement or the other documents and instruments
to be executed and delivered by Novartis pursuant hereto or the consummation of
the transactions contemplated hereby and thereby. This Agreement and the other
documents and instruments to be executed and delivered by Novartis pursuant to
this Agreement will, upon such execution and delivery, constitute valid and
binding agreements of Novartis, enforceable in accordance with their respective
terms, except as such may be limited by bankruptcy, insolvency, reorganization
or other laws affecting creditors' rights generally, and by general equitable
principles.
Section 4.3 Consents and Approvals; No Violation.
(a) Neither the execution and delivery of this Agreement or
the other documents and instruments to be executed and delivered by Novartis
pursuant hereto, nor the consummation by Novartis of the transactions
contemplated hereby and thereby require Novartis to obtain any Consent of any
Governmental Authority, or any third party.
(b) Neither the execution or delivery of this Agreement or the
other documents and instruments to be executed and delivered by Novartis, nor
the consummation by Novartis of the transactions contemplated hereby or thereby,
nor compliance by Novartis with any of the provisions hereof or thereof will (i)
conflict with any provision of Novartis' Certificates of Incorporation or
By-Laws, (ii) result in a material breach of, or default under, any of the
terms, conditions or provisions of any note, bond, mortgage, indenture, license,
agreement, lease or other instrument or obligation to which Novartis is a party,
or by which Novartis may be bound, or (iii) violate in any material respect any
order, judgment, writ, injunction, decree, statute, rule or regulation
applicable to Novartis or any of its assets or properties.
Section 4.4 No Brokers or Finders. No broker, finder,
investment banker, financial advisor or other Person is entitled to any
brokerage fees, commissions, finder's fees or financial advisory fees in
connection with this Agreement, or the transactions contemplated
6
10
hereby, by reason of any action taken by or on behalf of Novartis or any of its
officers, directors, representatives or agents.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF NOVEN
Noven makes the following representations and warranties to
Novartis, each of which is true and correct on the date hereof:
Section 5.1 Organization and Standing. Noven is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware
Section 5.2 Authority. Noven has all requisite corporate power
and authority to execute, deliver and perform its obligations under this
Agreement and the other documents and instruments to be executed and delivered
by Noven pursuant hereto and to consummate the transactions contemplated hereby
and thereby. The execution and delivery of this Agreement and the other
documents and instruments to be executed and delivered by Noven pursuant hereto
and the consummation of the transactions contemplated hereby and thereby have
been duly authorized by the Board of Directors of Noven. No other or further
corporate act or proceeding on the part of Noven or its shareholders is
necessary to authorize this Agreement or the other documents and instruments to
be executed and delivered by Noven pursuant hereto or the consummation of the
transactions contemplated hereby and thereby. This Agreement and the other
documents and instruments to be executed and delivered by Noven pursuant to this
Agreement will, upon such execution and delivery, constitute valid and binding
agreements of Noven, enforceable in accordance with their respective terms,
except as such may be limited by bankruptcy, insolvency, reorganization or other
laws affecting creditors' rights generally, and by general equitable principles.
Section 5.3 Consents and Approvals; No Violation.
(a) Neither the execution and delivery of this Agreement or
the other documents and instruments to be executed and delivered by Noven
pursuant hereto, nor the consummation by Noven of the transactions contemplated
hereby and thereby require Noven to obtain any Consent of any Governmental
Authority, or any third party.
(b) Neither the execution or delivery of this Agreement or the
other documents and instruments to be executed and delivered by Noven, nor the
consummation by Noven of the transactions contemplated hereby or thereby, nor
compliance by Noven with any of the provisions hereof or thereof will (i)
conflict with any provision of Noven's Certificates of Incorporation or By-Laws,
(ii) result in a material breach of, or default under, any of the terms,
conditions or provisions of any note, bond, mortgage, indenture, license,
agreement, lease or other instrument or obligation to which Noven is a party, or
by which Noven may be bound, or (iii) violate in any
7
11
material respect any order, judgment, writ, injunction, decree, statute, rule or
regulation applicable to Noven or any of its assets or properties.
Section 5.4 No Brokers or Finders. Except for ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ Inc., no broker, finder, investment banker, financial advisor or other
Person is entitled to any brokerage fees, commissions, finder's fees or
financial advisory fees in connection with this Agreement, or the transactions
contemplated hereby, by reason of any action taken by or on behalf of Noven or
any of its officers, directors, representatives or agents.
ARTICLE VI
MISCELLANEOUS
Section 6.1 Notices. All notices, requests, demands and other
communications hereunder shall be given in writing and shall be: (a) personally
delivered; (b) sent by telecopier, facsimile transmission or other electronic
means of transmitting written documents; or (c) sent to the Parties at their
respective addresses indicated herein by registered or certified U.S. mail,
return receipt requested and postage prepaid, or by private overnight mail
courier service. The respective addresses to be used for all such notices,
demands or requests are as follows:
(a) If to Noven, to:
Noven Pharmaceuticals, Inc.
▇▇▇▇▇ ▇.▇. ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, President and
Chief Executive Officer
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to:
▇▇▇▇▇ & ▇▇▇▇▇▇▇
▇▇▇▇ ▇ ▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇
Attention: ▇▇▇▇▇ ▇▇▇▇▇, Esq.
or to such other person or address as Noven shall furnish to
Novartis in writing.
(b) If to Novartis, to:
Novartis Pharmaceuticals Corporation
▇▇ ▇▇▇▇▇ ▇▇
▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: Office of the CEO
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
8
12
with copies to:
Novartis Pharmaceuticals Corporation
▇▇ ▇▇▇▇▇ ▇▇
▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Esq., Legal Department
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
and
White & Case LLP
▇▇▇▇ ▇▇▇▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇., Esq.
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
or to such other person or address as Novartis shall furnish
to Noven in writing.
If personally delivered, such communication shall be deemed delivered
upon actual receipt; if electronically transmitted pursuant to this paragraph,
such communication shall be deemed delivered on the day transmitted unless it is
received after 5:00 p.m., New York time, or on a day which is not a business
day, in which case it shall be deemed delivered on the next business day after
transmission (and sender shall bear the burden of proof of delivery); if sent by
overnight courier pursuant to this paragraph, such communication shall be deemed
delivered upon receipt; and if sent by U.S. mail pursuant to this paragraph,
such communication shall be deemed delivered as of the date of delivery
indicated on the receipt issued by the relevant postal service, or, if the
addressee fails or refuses to accept delivery, as of the date of such failure or
refusal. Any Party may change its address for the purposes of this Agreement by
giving notice thereof in accordance with this Section.
Section 6.2 Entire Agreement; Assignment. This Agreement,
including the exhibits hereto and the documents, schedules, certificates and
instruments referred to herein constitute the entire agreement, and supersede
all prior agreements and understandings, both written and oral, among the
parties with respect to the subject matter hereof. This Agreement shall not be
assigned by operation of law or otherwise.
Section 6.3 Parties in Interest. This Agreement shall be
binding upon and inure solely to the benefit of each Party hereto, and nothing
in this Agreement shall be deemed to confer upon any other Person any right or
remedy under or by reason of this Agreement.
9
13
Section 6.4 Law Governing Agreement. This Agreement shall be
construed and interpreted according to the internal laws of the State of New
York, excluding any choice of law rules that may direct the application of the
laws of another jurisdiction.
Section 6.5 Expenses. Each of the Parties shall bear its own
expenses and the expenses of its counsel and other agents in connection with the
transactions contemplated hereby.
Section 6.6 Headings. The headings in this Agreement are
inserted for convenience only and shall not constitute a part hereof.
Section 6.7 Counterparts. This Agreement may be executed in
one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Delivery of an
executed counterpart of a signature page to this Agreement by telecopier shall
be as effective as delivery of a manually executed counterpart of this
Agreement.
Section 6.8 Mutual Drafting Acknowledgment. This Agreement is
the result of the joint efforts of the Parties hereto and each provision hereof
has been subject to the mutual consultation, negotiation and agreement of the
parties and their counsel, and there shall be no construction against any Party
based upon any presumption of that Party's involvement in the drafting hereof.
Section 6.9 Amendment and Modification. This Agreement may be
amended, modified and supplemented only in a writing executed by the parties
hereto.
10
14
IN WITNESS WHEREOF, the Parties hereto have duly executed this
Agreement as of the date and year first above written.
NOVARTIS PHARMACEUTICALS CORPORATION
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------------------------
Title: President and Chief Executive Officer
NOVEN PHARMACEUTICALS, INC.
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-----------------------------------------------
Title: President and Chief Executive Officer